At 8:30 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the pricing of its underwritten public offering of $200.0 million aggregate principal amount of its 2.50% convertible senior notes due 2032 (the “Convertible Notes” and ...

WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that it has commenced underwritten public offerings of its convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering ...

Core Insights - ENAVATE Sciences GP, LLC increased its stake in Zenas BioPharma by purchasing 157,800 shares, valued at approximately $5.19 million based on quarterly average pricing [2][6] - The value of Zenas BioPharma's position in ENAVATE's portfolio rose by $58.80 million during the quarter, reflecting both the share purchase and stock price appreciation [2][6] - Zenas BioPharma now constitutes 28.08% of ENAVATE's reportable assets under management (AUM), making it the largest holding in the fund [6][7] Company Overview - Zenas BioPharma is a clinical-stage biotechnology company focused on developing therapies for autoimmune and rare immunological diseases [6][8] - The company has a pipeline that includes several monoclonal antibodies and fusion proteins aimed at addressing significant unmet medical needs [9] - As of March 20, 2026, Zenas BioPharma's stock price was $22.30, reflecting a 167% increase compared to one year prior, significantly outperforming the S&P 500 [7] Financial Metrics - As of the latest market close, Zenas BioPharma's market capitalization is approximately $932.9 million, with a trailing twelve months (TTM) revenue of $10 million and a TTM net income of -$377.7 million [4] - After the recent purchase, ENAVATE holds a total of 3,919,159 shares of Zenas BioPharma, valued at $142.30 million at quarter-end [6][10] Strategic Insights - ENAVATE's investment strategy focuses on high-conviction positions in specific biotech companies, rather than diversifying across a broad range of investments [11] - Zenas BioPharma is expected to submit a Biologics License Application (BLA) to the FDA for its lead candidate obexelimab in Q2 2026, with significant upcoming data releases that could impact its valuation [12]

Clinical Trials and Efficacy - Obexelimab demonstrated a 56% reduction in the risk of IgG4-RD flare compared to placebo in the Phase 3 INDIGO trial, with a Hazard Ratio of 0.44 (p=0.0005) and met all key secondary endpoints [17]. - The Phase 2 MoonStone trial for relapsing multiple sclerosis (RMS) showed a 95% relative reduction in new gadolinium-enhancing lesions compared to placebo (p=0.0009) at the 12-week primary endpoint [18]. - Obexelimab has been evaluated in eight clinical trials with a total of 383 subjects, demonstrating a well-tolerated safety profile and clinical activity [29]. - In the IgG4-RD trial, 80% of patients showed a reduction in disease score, with 67% achieving complete remission [50]. - The Phase 2 trial of obexelimab in SLE showed a treatment difference of 17.3% in the ITT population (40.4% obexelimab vs. 23.1% placebo, p=0.06) [51]. - The Phase 2 trial of obexelimab for IgG4-RD included 20 patients, with 15 receiving 5 mg/kg IV every two weeks for 24 weeks [68]. - The Phase 2 trial showed that 21 out of 50 (42.0%) obexelimab-treated patients achieved the primary endpoint, although not statistically significant (p = 0.183) [100]. - Obexelimab demonstrated a 42.0% response rate in the EE population compared to 28.6% in the placebo group, with a treatment difference of 17.3% in the ITT analysis [100]. - The overall safety profile of obexelimab was favorable, with the majority of TEAEs being mild or moderate across multiple studies [107]. - The most common treatment-emergent adverse events included abdominal pain and nausea (20%), with no new safety signals observed at week 24 [76][79]. Product Development and Commercialization - The company plans to submit a Biologics License Application (BLA) for obexelimab to the FDA in Q2 2026 and a Marketing Authorization Application (MAA) to the EMA in the second half of 2026 [17]. - Each of the indications for obexelimab, including IgG4-RD, RMS, and systemic lupus erythematosus (SLE), represents a multi-billion-dollar commercial opportunity in the U.S. alone [16]. - The company has no product candidates approved for commercial sale and has not generated any revenue from product sales to date [25]. - The company plans to leverage initial successes to expand into broader I&I opportunities and evaluate strategic collaborations for commercialization [43]. - A recent licensing agreement secured rights to develop and commercialize orelabrutinib in MS worldwide, excluding greater China and Southeast Asia [43]. - The company plans to initiate a second Phase 3 trial for orelabrutinib in non-active SPMS in the first quarter of 2026, enrolling approximately 990 patients [140]. Intellectual Property and Licensing Agreements - The company owns or exclusively in-licenses 28 patent families covering various product candidates, with expiration dates ranging from 2027 to 2047 [194]. - The company has 14 patent families specifically covering obexelimab, with the first patent family expiring in May 2028 and others extending to October 2044 [197][198]. - The company entered into a License Agreement with InnoCare, making a one-time non-refundable upfront cash payment of $35.0 million and issuing 5,000,000 shares of common stock as partial consideration [185]. - The company received a one-time upfront payment of $50.0 million under the BMS Agreement, with potential milestone payments totaling up to $79.5 million for development and regulatory achievements, and up to $70.0 million for sales milestones [179]. - The last-to-expire patent under the BMS Agreement is set to expire on October 2, 2044, assuming all applications are allowed [180]. Future Developments and Pipeline - Orelabrutinib is being advanced in a Phase 3 trial for Primary Progressive Multiple Sclerosis (PPMS) and a second Phase 3 trial for non-active Secondary Progressive Multiple Sclerosis (SPMS) is expected to initiate in Q1 2026 [21]. - ZB021, an oral IL-17AA/AF inhibitor, is expected to initiate Phase 1 clinical studies in 2026, with initial data anticipated in 2027 [34]. - ZB022, a brain-penetrant TYK2-JH2 inhibitor, is in IND-enabling studies, with an IND application expected in 2026 [23]. - The company is also developing ZB014, an anti-CD-19 and FcγRIIb monoclonal antibody currently in pre-clinical studies [121]. Management and Strategy - The management team has extensive experience in biopharmaceuticals, having been responsible for numerous INDs and successful product launches [38]. - The strategy includes developing obexelimab for multiple I&I indications, with ongoing Phase 2 trials for RMS and SLE, and a Phase 3 trial for IgG4-RD [43].

Core Insights - Zenas BioPharma is preparing to submit marketing applications for obexelimab for IgG4-RD to the FDA in Q2 2026 and to the EMA in H2 2026, following positive Phase 3 INDIGO trial results [1][4] - The company anticipates topline results from the Phase 2 SunStone trial for systemic lupus erythematosus (SLE) in Q4 2026 [1][4] - Zenas has secured up to $250 million in non-dilutive debt financing from Pharmakon, enhancing its financial flexibility for commercialization and pipeline investments [1][6] Corporate Highlights - Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, showing a 56% reduction in IgG4-RD flare risk compared to placebo in the INDIGO trial [4][12] - The company is advancing multiple pipeline programs, including orelabrutinib for multiple sclerosis (MS) and ZB021, an oral IL-17AA/AF inhibitor, with Phase 1 trials expected to start in Q2 2026 [2][3][7] - ZB014, a new half-life extended anti-CD-19 and FcγRIIb antibody, is also progressing toward clinical development [3][4] Financial Results - For the year ended December 31, 2025, Zenas reported revenue of $10 million, primarily from a license agreement, compared to $5 million in 2024 [10][11] - Research and development expenses increased to $168.1 million in 2025 from $139.1 million in 2024, driven by higher personnel and clinical trial costs [13][21] - The net loss for the year was $377.7 million, compared to a net loss of $157.0 million in 2024 [13][21] Balance Sheet - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $360.5 million, up from $350.8 million in 2024 [22] - Total liabilities increased to $141.5 million from $57.5 million in 2024, reflecting the new debt facility [22] - The accumulated deficit reached $765.1 million as of December 31, 2025, compared to $387.4 million in 2024 [22]

Core Thesis - Zenas BioPharma, Inc. is viewed positively due to its transition from a pre-revenue stage to commercialization, with projected revenues rising to $30 million by 2026 and significant growth thereafter [2][5] Company Overview - Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies [2] - The company's lead asset, obexelimab, targets IgG4-Related Disease (IgG4-RD), a market currently lacking approved therapies, providing a unique at-home treatment option [2] Product Potential - Obexelimab's mechanism via CD19/FcγRIIb preserves patients' immune systems, presenting a potential competitive advantage, although recent trial data indicated efficacy may not meet "best-in-class" expectations [3] - The drug is also being tested for Warm Autoimmune Hemolytic Anemia and Multiple Sclerosis, positioning Zenas for a long-term role in treating B-cell-mediated autoimmune diseases [3] Financial Position - As of early 2026, Zenas had approximately $270 million in cash, which is expected to support operations through 2028 [4] - The company has expanded its pipeline through in-licensing strategies, reducing early-stage discovery risks [4] Market Valuation - Current market focus on hazard ratio metrics may undervalue ZBIO, which is trading at a significant discount to its potential [5] - With successful regulatory filings and commercialization, Zenas could achieve a market capitalization up to five times its current value, indicating a high-risk, high-reward investment opportunity [5]

Core Insights - The Meridian Small Cap Growth Fund reported a 0.90% net return in Q4 2025, underperforming the Russell 2000 Growth Index, which returned 1.22% [1] - Small caps achieved an annual return of 12.8% with a 2.2% gain in Q4 2025, indicating a positive overall market performance despite some cooling in sentiment [1] Company Highlights - Zenas BioPharma, Inc. (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on autoimmune diseases, with its lead drug Obexelimab in Phase 3 trials, potentially launching in 2027 [3] - Zenas BioPharma's stock saw a one-month return of 30.78% and a remarkable 241.61% increase over the past 52 weeks, closing at $26.68 per share with a market cap of $1.432 billion on February 18, 2026 [2][3] - The company has the potential for annual revenues exceeding $1 billion, contingent on successful drug development and regulatory approval [3] Investment Sentiment - Zenas BioPharma is not among the top 30 most popular stocks among hedge funds, with 13 hedge fund portfolios holding its shares at the end of Q3 2025, unchanged from the previous quarter [4] - While Zenas BioPharma is recognized for its potential, the company is viewed as having less upside compared to certain AI stocks, which are considered to carry less downside risk [4]

Summary of Zenas BioPharma Conference Call Company Overview - **Company**: Zenas BioPharma (NasdaqGS: ZBIO) - **Event**: Guggenheim Emerging Outlook Biotech Summit 2026 - **Date**: February 11, 2026 Key Points on IgG4-RD and Obexelimab - **Pipeline Focus**: The primary focus is on obexelimab and its application in IgG4-related disease (IgG4-RD) [2][3] - **INDIGO Phase 3 Study Results**: - Reported a **56% risk reduction** in time to disease flare with a hazard ratio of **0.4** [3] - Approximately **75% of patients** were free from flares, indicating strong efficacy [3] - In the open-label extension, **92% of evaluable patients** remained flare-free at six months [4] - **Safety Profile**: - Serious adverse events were comparable to placebo, with no significant increase in infections [4][5] - The subcutaneous administration showed similar injection site reactions to placebo, enhancing its safety profile [5] Market Research Insights - **Market Research Study**: Conducted with **80 participants**, primarily rheumatologists and gastroenterologists [6] - **Prescribing Likelihood**: - **64%** of physicians indicated they would likely prescribe obexelimab [8] - Expected market share allocation: **47%** for obexelimab, with the remainder split between Uplizna and rituximab [8] - **Patient Population Insights**: - Physicians reported treating an average of **18 patients** per year with IgG4-RD [6] - The drug is seen as suitable for older patients or those with concurrent illnesses [9] Commercialization Strategy - **Market Opportunity**: Estimated market size for IgG4-RD treatment in the U.S. is between **$3-$4 billion**, with expectations for obexelimab to exceed **$1 billion** in sales [41][42] - **Patient Population**: Approximately **20,000 diagnosed patients** in the U.S. currently, with potential for growth through increased education and diagnosis [40] - **Launch Timeline**: - BLA filing expected in **Q2 2026** for the U.S. and in the second half of the year for Europe [56] - Initial launch will feature prefilled syringes, followed by an autoinjector within a year [56] Lupus Program Insights - **Sunstone Study**: - Results expected in **Q4 2026**, focusing on the **BICLA primary endpoint** [62] - Emphasis on strict screening criteria to ensure a pure patient population for accurate results [65] - **Biomarker Program**: A gene pattern identified in **30% of lupus patients** may indicate higher responsiveness to treatment [80] BTK Inhibitor Insights - **Orelibrutinib**: Positioned as a potent option for progressive MS, with ongoing trials to demonstrate its efficacy [90] - **Comparison with Competitors**: Fenebrutinib showed promising results compared to Ocrevus, indicating a competitive landscape for BTK inhibitors [88] Future Developments - **New Molecules**: - TYK2 and IL-17 oral molecules are set to enter clinical trials soon, with promising characteristics noted [95][97] - **Rapid Development**: The IL-17 molecule is expected to move quickly through clinical phases, with outcomes anticipated by the end of the year [97] Conclusion - Zenas BioPharma is positioned to capitalize on its robust pipeline, particularly with obexelimab for IgG4-RD, and is preparing for significant market entry and expansion in the coming years. The company is also actively pursuing additional indications, including lupus and progressive MS, with a focus on safety and efficacy in patient populations.

Core Insights - Obexelimab demonstrated a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo in the Phase 2 MoonStone trial, indicating significant efficacy in treating Relapsing Multiple Sclerosis (RMS) [1][2] - The 24-week data further confirmed the drug's robust and durable activity, maintaining significant reductions in lesions and improving biomarkers associated with disease activity [3][4] - The safety profile of obexelimab was consistent with previous trials, showing good tolerability without new safety signals [2][3] Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [12] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib, with obexelimab being the lead candidate targeting B cell activity [12] - Zenas plans to submit a Biologics License Application (BLA) for obexelimab in the second quarter of 2026 and a Marketing Authorization Application (MAA) in the second half of 2026 for Immunoglobulin G4-Related Disease [11][12] Clinical Trial Details - The Phase 2 MoonStone trial enrolled 116 patients and was designed to evaluate the efficacy and safety of obexelimab in RMS, using MRI endpoints to measure treatment outcomes [9] - The trial's primary endpoint was the cumulative number of new gad-enhancing T1 lesions over weeks 8 and 12, with secondary endpoints assessing disease progression through various biomarkers [9] - Following the double-blind phase, patients transitioned to an open-label period to continue treatment and assess long-term outcomes [9] Mechanism of Action - Obexelimab is a bifunctional monoclonal antibody that binds to CD19 and FcγRIIb, inhibiting B cell activity without depleting them, which is crucial for addressing autoimmune diseases [10][12] - The drug's unique mechanism and self-administered subcutaneous injection regimen may effectively target the pathogenic role of B cells in chronic autoimmune conditions [10][12]